According to reports, the Union Cabinet decided to not discuss the National Pharmaceutical Pricing Policy (NPPP) in a recent meeting due to concerns over the NPPP’s price-fixing mechanism policy. The finance ministry raised concerns over the NPPP, and, as a result, the delay in discussion threatens to prevent the NPPP from being finalized and submitted to the Supreme Court by its given deadline of November 25. A group of ministers had originally suggested the price-fixing mechanism, though the finance ministry has found loopholes in its legislature.
Featured News
American Express Loses Appeal Seeking Arbitration of Merchants’ Antitrust Claims
Aug 20, 2026 by
CPI
Portugal Rail Market Faces Competition Push as Regulator Targets Barriers
Aug 20, 2026 by
CPI
France Fines Boohoo €2.3 Million as Scrutiny of Fast-Fashion Pricing Intensifies
Aug 20, 2026 by
CPI
California AG Seeks Structural Fixes in Paramount-Warner Antitrust Fight
Aug 20, 2026 by
CPI
Australia Targets Big Tech With New Levy to Fund Local News
Aug 20, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes